Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
Jump to:
| Id | http://purl.obolibrary.org/obo/NCIT_C2007
http://purl.obolibrary.org/obo/NCIT_C2007
|
|---|---|
| Preferred Name | Brentuximab |
| Definitions |
A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Brentuximab specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkin lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Brentuximab specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkin lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations. |
|---|---|
| label |
Brentuximab
|
| prefLabel |
Brentuximab
|
| Legacy Concept Name |
SGN-30
|
| in_subset |
See more
See less
|
| Preferred_Name |
Brentuximab
|
| Is_Value_For_GDC_Property | |
| Display_Name |
Brentuximab
|
| Maps_To |
Brentuximab
|
| PDQ_Open_Trial_Search_ID |
357600
|
| Has_Target | |
| UMLS_CUI |
C1328236
|
| FDA_UNII_Code |
C67ORA155P
|
| prefixIRI |
NCIT:C2007
|
| NCI_Drug_Dictionary_ID |
357600
|
| Contributing_Source |
CTRP
FDA
|
| subClassOf | |
| code |
C2007
|
| type | |
| ALT_DEFINITION |
A monoclonal antibody that binds to cells that have the CD30 antigen on their surface, including Hodgkin disease cells and cells from anaplastic large cell lymphoma, and cutaneous T-cell lymphoma. SGN-30 is being studied in the treatment of cancer. It is a type of monoclonal antibody.
|
| NSC Number |
731636
|
| PDQ_Closed_Trial_Search_ID |
357600
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| CAS_Registry |
775303-41-8
|
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |